ClinicalTrials.gg
Not yet recruitingNCT05467553Updated Dec 29, 2022

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

A Phase 2 interventional study of Ursodeoxycholic acid and Ropeginterferon alfa-2b in Hepatitis D, sponsored by National Taiwan University Hospital. Not yet recruiting at 2 sites in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-29.

Sponsored by National Taiwan University Hospital · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.

Read the detailed description

There will be 2 treatment groups in this study, 15 subjects per group as follows:

Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Group 2: Ursodeoxycholic Acid (UDCA)* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Both groups will have a post-treatment follow-up of 24 weeks.

*: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses.

02

Conditions studied

  • Hepatitis D

Browse trials for

Keywords

  • Ropeginterferon alpha-2b, Hepatitis D, UDCA, TAF
03

In context

Hepatitis D

63 studies on the registry are indexed under Hepatitis D; 21 are open to participants now.

This study's planned enrollment of 30 is below the median of 80 across 30 interventional studies indexed under Hepatitis D.

Browse Hepatitis D studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Positive for for at least 6 months, either HBeAg(+) or HBeAg(-), and positive for anti-HDV with detectable HDV RNA and ≥ to ≤ 10X ULN at screening.
  2. Interferon treatment naïve.
  3. Willing and able to provide written .
  4. Age 20-75 years old; subjects who are over 70 years of age must be in generally good health.
  5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ≥ 1,500/mm3; ≥ 90,000/mm3; ≥ 10g/dL; e- ≥ 60mL/min.
  6. without abnormalities before study entry.
  7. Be able to attend all scheduled visits and to comply with all study procedures.
  8. Patients with anti-(+) or anti-(+) can be enrolled if:

    1. anti-HCV(+) with undetectable HCV RNA ≥ 3 months.
    2. anti-HIV(+) with undetectable HIV viral load (either with or without Highly Active Anti- Retroviral Therapy, HAART).

Exclusion criteria

Exclusion Criteria:

  1. illness or surgery that might interfere with study participation.
  2. Clinically significant vital sign abnormalities, uncontrolled hypertension, or fever [body temperature >38 degrees Celsius].
  3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study.
  4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular, pulmonary, hematologic, immunologic, diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias.
  5. Pregnant subject; female subject who are breast feeding or lactating; female subject or the spouse of male subject, with who is unwilling or unable to practice adequate , defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study.
  6. History of severe allergic or reactions, e.g. hypersensitivity to the active substance or to any of the of ropeginterferon alfa 2b, ursodeoxycholic acid, tenofovir disoproxil fumarate and tenofovir alafenamide.
  7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug.
  8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis.
  9. Body organ transplant or taking .
  10. Use of an drug within 4 weeks prior to the first dose of the study drug.
  11. History of diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ); cancer survivors not on maintenance therapy within the past 5 years.
  12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
  13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening.
  14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs.
  15. Decompensated liver disease, which includes but not limited to the following: total ≥ 2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥ 2X , albumin level \< 3.5 g/dL, ≥ 1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry.
  16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator.
  17. Other form of significant chronic liver diseases, except those mentioned above.
  18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macu-lar changes.
  19. Patients with complete biliary obstruction, chololithiasis, severe pancreatic disease or peptic ulcer.
  20. Patients treated by monotherapy of telbivudine/TDF/TAF/adefovir dipivoxil or any other combination therapy with telbivudine/TDF/TAF/adefovir dipivoxil within 1 month prior to screening.
  21. Patient who vaccination with any within 1 month prior to screening.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    TAF and P1101 combination therapy with UDCA

    Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

    Drug: Ursodeoxycholic acid · Drug: Ropeginterferon alfa-2b · Drug: Tenofovir Alafenamide

  • Active comparator
    TAF and P1101 combination therapy without UDCA

    TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

    Drug: Ropeginterferon alfa-2b · Drug: Tenofovir Alafenamide

Interventions

06

What researchers measure

Primary outcomes

  1. HDV RNA level

    Decline in HDV RNA ≥ 2 log10 IU/mL at Week 60

    Time frame: Week 60

  2. ALT level

    ALT normalization (ALT \< upper limit of normal) at Week 60

    Time frame: Week 60

Secondary outcomes

  1. Undetectable HDV RNA

    Undetectable HDV RNA (HDV RNA\< low limit of quantifica-tion) at Week 60 and Week 84

    Time frame: Week 60 and Week 84

  2. HBsAg level

    Reduction in HBsAg ≥ 1 log10 IU/mL at Week 60 and Week 84

    Time frame: Week 60 and Week 84

  3. Undetectable HBsAg

    HBsAg loss at Week 60 and Week 84

    Time frame: Week 60 and Week 84

  4. HBsAg and anti-HBs level

    HBsAg seroconversion (HBsAg loss plus positive anti-HBs) at Week 60 and Week 84

    Time frame: Week 60 and Week 84

  5. HDV RNA level

    Decline in HDV RNA ≥ 2 log10 IU/mL at Week 84

    Time frame: Week 84

  6. ALT level

    ALT normalization (ALT \< upper limit of normal) at Week 84

    Time frame: Week 84

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05467553
Collaborators
PharmaEssentia
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Feb 24, 2023 (estimated)
Primary completion
Feb 28, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Dec 29, 2022

Study contacts

Pei-Jer Chen
Contact
peijerchen@ntu.edu.tw
886-2-23123456 ext. 67072
Pei-Jer Chen
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ursodeoxycholic Acid

Start the discussion